Dupixent® (dupilumab) long-term data show sustained improvement in lung function and reduction in severe exacerbations in adults and adolescents with moderate-to-severe asthma

NEXT STORY
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum
PREV STORY
Everest Medicines Announces First Patient Randomized in a Phase 3 Clinical Study of Nefecon for IgA Nephropathy Patients in China
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Amolyt Pharma Exercises Option to License Optimized Acromegaly Drug Candidate from PeptiDream as it Continues to Build its Rare Endocrine Pipeline

author_avatar
NASDAQ Market News

Orion has started a Phase III trial to develop a drug for ALS – The patient recruitment has begun

ORION CORPORATION                                                                         PRESS RELEASE                                                                         6 JULY 2018 AT 11.00 EEST             Orion has ...

author_avatar
NASDAQ Market News

More Doctors Say Yes to Biosimilars, But With Increased Caution Than 6 Months Ago, Says New Data from InCrowd

BOSTON, MA--(Marketwired - Nov 16, 2016) - As the FDA approves more biosimilars -- ...

author_avatar
NASDAQ Market News